On January 1, 2026, Pennsylvania's Medical Assistance program stopped covering GLP-1 medications for adult weight loss. Roughly 27,000 Pennsylvanians lost coverage for Wegovy, Saxenda, and similar prescriptions. The change does not affect diabetes coverage. Patients with a Type 2 diabetes diagnosis continue to get coverage for Ozempic, Mounjaro, and other GLP-1s when prescribed for glycemic control. Patients under 21 also retain coverage under federal EPSDT rules.
For everyone else in the state, the question of how to keep treatment going has been about finding an affordable cash-pay path. This guide walks through what coverage still exists, what the realistic price tiers look like, and what to watch for when comparing options.
What changed on January 1, 2026
The Pennsylvania Department of Human Services announced the change in late 2025 as part of a broader effort to close a $348.3 million budget gap projected over fiscal year 2025 to 2026, growing to roughly $836 million by FY 2026 to 2027. The mechanism was a Medical Assistance Bulletin updating the preferred drug list to remove obesity as a covered indication for the GLP-1 class.
Pennsylvania is not alone. California, New Hampshire, and South Carolina made similar moves in late 2025. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity, down from 16 in October 2025. The pattern is driven by the same math everywhere: a single patient on Wegovy at the wholesale acquisition cost can run a state Medicaid program more than $12,000 per year before rebates, and uptake has been faster than budgets anticipated.
What still gets covered
- Type 2 diabetes: Pennsylvania Medical Assistance continues to cover semaglutide (Ozempic, Rybelsus), tirzepatide (Mounjaro), and other GLP-1s for adults with a documented Type 2 diabetes diagnosis when prescribed for glycemic control. Prior authorization is generally required.
- Patients under 21: Federal EPSDT rules require state Medicaid programs to cover medically necessary services for beneficiaries under 21, which Pennsylvania interprets to include GLP-1 medications for adolescent obesity meeting clinical criteria.
- Cardiovascular indications: The FDA approved semaglutide 2.4 mg (Wegovy) for cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease in 2024. Pennsylvania's policy specifically excludes weight loss as an indication, but coverage decisions for the CV indication have been case-by-case in early 2026. Patients with documented ASCVD should have their physician submit prior authorization with the CV indication documented.
- Commercial insurance: Pennsylvania-regulated commercial plans (Highmark, Independence Blue Cross, UPMC Health Plan, Geisinger Health Plan, Aetna) set their own coverage policies independently of the Medicaid change. Most commercial plans cover Wegovy or Zepbound for adults meeting BMI criteria, often with prior authorization and step therapy requirements.
The cash-pay landscape, ranked by cost
For Pennsylvania patients without coverage, the realistic options sort into four tiers. Prices below are 2026 averages and can vary by pharmacy and dose.
Tier 1: Branded retail, no insurance, no manufacturer program
The list price for Wegovy at retail pharmacy without insurance runs approximately $1,349 per month. Zepbound (tirzepatide) runs $1,059 to $1,250 per month at retail. These numbers are essentially the cap; almost no one actually pays this in 2026 because the manufacturer direct programs and compounded options have made cheaper paths available to most patients.
Tier 2: Manufacturer direct programs
Novo Nordisk's NovoCare Pharmacy program offers all doses of Wegovy at $499 per month for cash-pay patients. Eli Lilly's LillyDirect offers Zepbound starting at $349 per month for the lower doses (2.5 mg and 5 mg vials) and $449 per month for higher doses, also cash-pay. Both programs require enrolling through the manufacturer's portal and shipping directly. The doses match the branded product exactly. The catch is that these programs depend on continued manufacturer participation, which has shifted multiple times since 2024 and could change again.
Tier 3: Compounded semaglutide and tirzepatide via telehealth
State-licensed 503A compounding pharmacies prepare semaglutide and tirzepatide for individual patients with a prescription from a licensed physician. Pricing in Pennsylvania typically runs $179 to $349 per month depending on dose, pharmacy, and whether the patient is on a monthly or multi-month plan. Compounded products are legal under federal pharmacy law when prepared for a specific patient with documented medical necessity or a significant difference from the commercial product.
The semaglutide and tirzepatide shortages that previously authorized broader compounding ended in February 2025 (semaglutide) and December 2024 (tirzepatide). Compounding has continued under 503A rules with documented patient-specific justification. The FDA has issued guidance on this and proposed adding semaglutide, tirzepatide, and liraglutide to its 503B Bulks List restriction (public comment closed June 29, 2026). Patients considering compounded options in 2026 should verify the pharmacy is state-licensed, that the prescriber is licensed in Pennsylvania, and that the program has appropriate clinical oversight.
Tier 4: HSA and FSA reimbursement
For patients with a Health Savings Account or Flexible Spending Account, GLP-1 medications can typically be reimbursed when accompanied by a Letter of Medical Necessity from a treating physician. This is not a discount; it's a tax-advantaged way to pay. The effective discount depends on the patient's marginal tax rate but typically lands in the 22 to 32 percent range for most working-age Pennsylvanians. HSA and FSA reimbursement applies to both branded and compounded products as long as a valid prescription and LOMN are documented.
What patients losing Medicaid coverage are doing
Based on patient inquiries through the first quarter of 2026, three patterns are common.
Pattern 1: Switch from branded to manufacturer-direct. Patients who were on Wegovy through Medical Assistance often move to NovoCare's $499 per month direct program. Same molecule, same dose, same FDA-approved product, just a different payment route. This is the simplest transition because the prescription itself doesn't need to change.
Pattern 2: Switch from branded to compounded. The cost difference between $499 per month and $179 to $249 per month for compounded preparations is significant for a medication most patients stay on long-term. Patients making this switch should work with a physician who can document the clinical justification appropriate to a 503A compounded prescription.
Pattern 3: Move to a diabetes indication if applicable. A subset of patients on GLP-1s for weight loss actually meet clinical criteria for Type 2 diabetes or prediabetes that hadn't been formally documented. For these patients, re-evaluation by a primary care physician can shift the prescription onto a covered indication. This requires a real diagnosis based on labs, not a workaround.
What to watch for when comparing
Total cost, not list price
Comparing $179 per month to $499 per month is straightforward only if both include shipping, supplies (syringes, alcohol pads), provider visits, and refill processing. Compounded telehealth programs vary widely in what's bundled. Ask for the all-in monthly cost.
Pharmacy licensing
Pennsylvania law requires that any pharmacy dispensing prescriptions to Pennsylvania residents holds either a Pennsylvania pharmacy license or a nonresident pharmacy license issued by the Pennsylvania Department of State. Patients should verify license status through the Department's online lookup before sending payment to an out-of-state pharmacy.
Provider licensing
The prescribing physician or advanced practice provider must be licensed to practice in Pennsylvania. Pennsylvania does not require an in-person visit before prescribing via telehealth, but the practitioner-patient relationship must be established through synchronous video or phone evaluation.
Dose flexibility
The lowest cash-pay tier sometimes locks patients into a specific dose for the duration of a paid plan. Patients who need to titrate up or down (which is the norm with GLP-1 therapy) should confirm that dose changes are included in the program at no additional cost.
What's in the vial
Patients should be able to ask the dispensing pharmacy for the active pharmaceutical ingredient source, the compounding standards followed, and the lot-level documentation. Reputable 503A pharmacies will provide this information. The Pennsylvania Department of State publishes inspection records for licensed compounding pharmacies.
Geographic considerations within Pennsylvania
The state's pharmacy density varies. The Philadelphia and Pittsburgh metros have the highest concentration of pharmacies licensed for sterile compounding, as well as the largest selection of telehealth providers operating in the state. Patients in rural Pennsylvania (especially the northern tier and the central rural counties) may have fewer in-person options but identical access to telehealth-based programs that ship to home addresses. Mailed cold-chain shipments require signature on delivery and refrigeration, which is logistically straightforward in most parts of the state but can be a consideration for patients who travel frequently or have inconsistent home delivery.
Frequently asked questions
If I had Medicaid coverage for Wegovy through 2025, do I have to start over with prior authorization to switch to NovoCare or a compounded program? You'll need a new prescription routed to the new pharmacy, but you don't need to repeat insurance prior authorization (since cash-pay programs don't use insurance). A new prescriber-patient relationship will need to be established if you're switching providers, which Pennsylvania allows via telehealth synchronous visit.
Can I appeal the Medicaid coverage decision? The change is a policy-level update to the preferred drug list, not a denial of an individual claim, so traditional appeals don't apply. Patients with documented medical necessity tied to a covered indication (diabetes, cardiovascular risk reduction) can have their physician submit prior authorization with the appropriate indication.
Is compounded semaglutide the same as Wegovy? Compounded preparations contain the same active pharmaceutical ingredient (semaglutide) when prepared by a state-licensed 503A pharmacy meeting USP standards. They are not FDA-approved finished products and they cannot be marketed as identical to the branded medication. The clinical effect is generally consistent when the compounding is done by a reputable pharmacy with proper API sourcing and documentation.
What happens if Pennsylvania reinstates coverage? If a future policy change restores weight-loss coverage, patients can transition back to insurance-covered branded medications by requesting a new prescription. The transition out of compounded preparations is straightforward; no medical washout is required between products containing the same active ingredient at therapeutic doses.
What's the FDA's position on compounded GLP-1s in 2026? The FDA reiterated in April 2026 that compounded products marketed as "essentially a copy" of an approved drug are not permitted under federal law. Compounding remains legal under 503A rules when prepared for an individual patient with documented clinical justification (significant difference from the commercial product, true medical necessity). The proposed 503B Bulks List exclusion of semaglutide, tirzepatide, and liraglutide is a separate regulatory track that primarily affects outsourcing facilities, not 503A patient-specific compounding.
The Bottom Line
Pennsylvania's Medical Assistance program no longer covers GLP-1s for adult weight loss as of January 1, 2026. Coverage remains for diabetes, for patients under 21, and case-by-case for the cardiovascular indication. For everyone else, the realistic cash-pay range runs from $179 per month (compounded, multi-month plan) to $499 per month (NovoCare direct Wegovy) to $1,349 per month (uninsured retail). Most patients can find a sustainable path; the gap is mostly informational, not financial.
CLYR Health operates a state-licensed 503A program serving Pennsylvania residents at flat-rate, any-dose pricing. Pennsylvania-licensed physicians, no in-person visit required, no hidden fees. Start your assessment at /intake.html.